Figitumumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade

Description of Figitumumab Biosimilar - Anti-IGF1R, CD221 mAb - Research Grade

Figitumumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade

Figitumumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade: A Promising Antibody for Targeting IGF1R in

Cancer Treatment Introduction

Figitumumab Biosimilar, also known as Anti-IGF1R, CD221 mAb, is a monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF1R). It is a biosimilar version of the original drug Figitumumab, which was developed by Pfizer for the treatment of cancer. Figitumumab Biosimilar is currently in the research grade stage and shows promising potential as a therapeutic antibody for treating various types of cancer.

Structure

Figitumumab Biosimilar is a humanized monoclonal antibody, meaning that it is derived from human antibodies and has been modified to reduce immune reactions. It is composed of two heavy chains and two light chains, with a molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab region is responsible for binding to the IGF1R receptor, while the Fc region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Activity

The main target of Figitumumab Biosimilar is the IGF1R, a transmembrane receptor that plays a crucial role in cell growth, proliferation, and survival. IGF1R is overexpressed in many types of cancer, making it an attractive therapeutic target. Figitumumab Biosimilar binds to the extracellular domain of IGF1R, preventing the binding of its natural ligands (insulin-like growth factor 1 and 2) and inhibiting downstream signaling pathways. This leads to the inhibition of cell growth and induction of cell death, making it a potential treatment for cancer.

In addition to its direct effects on

cancer cells, Figitumumab Biosimilar also has immunomodulatory properties. It can activate immune cells, such as natural killer (NK) cells and macrophages, through its Fc region, enhancing their ability to kill cancer cells. This makes Figitumumab Biosimilar a promising candidate for combination therapy with other immunotherapies.

Application

Figitumumab Biosimilar is being studied for its potential use in various types of cancer, including lung, breast, prostate, and pancreatic cancer. In preclinical studies, it has shown promising results in inhibiting tumor growth and inducing tumor regression. It has also been shown to sensitize cancer cells to chemotherapy and radiation therapy, making it a potential adjuvant therapy for these treatments.

Currently, Figitumumab Biosimilar is in the research grade stage, and clinical trials are underway to evaluate its safety and efficacy in cancer patients. If successful, it could potentially become a new treatment option for cancer patients, especially those with tumors that overexpress IGF1R and have limited treatment options.

Conclusion

Figitumumab Biosimilar is a promising antibody that targets the IGF1R receptor, which is overexpressed in many types of cancer. Its unique structure and activity make it a potential treatment option for cancer patients. Further research and clinical trials are needed to fully evaluate its potential and determine its role in cancer treatment. However, Figitumumab Biosimilar holds great promise in the fight against cancer and could potentially improve outcomes for patients with limited treatment options.

Figitumumab Biosimilar - Anti-IGF1R, CD221 mAb binds to IGF1R recombinant protein in indirect ELISA Assay

Immobilized IGF1R recombinant protein (cat. No.PX-P5185) at 0.5µg/mL (100µL/well) can bind to Figitumumab Biosimilar - Anti-IGF1R, CD221 mAb (cat. No.PX-TA1208) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450